Group 1 - The core viewpoint of the article is the strategic partnership established between Yabao Chemical and Hengrui Medicine through a supply strategic agreement aimed at collaborative management of the product lifecycle [1] - The agreement focuses on creating an end-to-end collaboration mechanism that includes process research and development, commercial production, and continuous improvement [1] - Yabao Chemical is confirmed as the strategic partner of Hengrui Medicine in the field of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) [1]

雅本化学公告，2025年8月1日，公司与恒瑞医药签署《供应战略协议》。双方就建立面向未来的战略合 作伙伴关系达成框架性协议，以共同推动特定医药中间体及原料药产品（API）的技术创新与质量升 级，强化医药产业链关键环节的协同竞争力，实现双方在医药先进制造领域的价值共赢。本协议为后续 双方推进具体项目合作奠定了基础，不涉及具体交易金额，最终能否实施尚存在不确定性。 ...

Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

Investment Rating - The industry rating is "Positive" for the next 12 months, indicating an expected increase in performance relative to the CSI 300 index [5][61]. Core Insights - Recent collaboration between Heng Rui Medicine and GSK is expected to boost sentiment in the innovative drug sector, highlighting investment opportunities in pipeline realization, performance growth, and business collaborations [5][60]. - The 11th batch of centralized procurement is underway, suggesting a focus on pharmaceutical and medical device sectors that may benefit from optimized procurement rules [5][60]. - The report emphasizes the importance of monitoring performance reversals in related sectors, particularly in CXO companies, which have shown strong performance amid improving overseas demand and recovering orders [5][60]. Industry News - The Central Committee of the Communist Party and the State Council issued a plan for the implementation of a childcare subsidy system, which may impact the healthcare sector positively [14]. - The National Healthcare Security Administration released guidelines for the immediate settlement of basic medical insurance funds, aiming to enhance efficiency in fund disbursement [14]. Company Announcements - Heng Rui Medicine signed a collaboration and licensing agreement with GSK, which includes a $500 million upfront payment and potential milestone payments totaling approximately $12 billion for successful project developments [28]. - WuXi AppTec reported a 20.64% year-on-year increase in revenue for the first half of 2025, with net profit rising by 101.92% [29]. - CSPC Pharmaceutical announced an exclusive licensing agreement with Madrigal for the development of SYH2086, with potential total payments of up to $2.075 billion [30]. - Tigermed announced the acquisition of a stake in Japan's MICRON for approximately ¥484 million (about 23.48 million RMB) [31]. Market Review - For the week of July 25 to July 31, 2025, the Shanghai Composite Index fell by 0.90%, while the Shenzhen Component Index dropped by 1.64%. In contrast, the pharmaceutical and biological sector rose by 2.74%, with most sub-sectors showing positive performance [52]. - As of July 31, 2025, the price-to-earnings ratio (TTM) for the pharmaceutical and biological industry was 30.83, with a valuation premium of 161% compared to the CSI 300 index [57].

Investment Rating - The report maintains a positive outlook on the pharmaceutical and biotechnology industry, emphasizing the transition from "Made in China" to "Created in China" for innovative drugs [10]. Core Insights - The report highlights that domestic innovative drugs are gaining global competitiveness and are currently in the first and second stages of international expansion, primarily through licensing agreements and partnerships [10][12]. - The report identifies key areas of focus for investment, including PD-(L)1 plus, ADCs, and GLP-1 drugs, which are expected to drive future growth and business development (BD) opportunities [10][51]. Summary by Sections Section 1: Transition from "Manufacturing" to "Innovation" - The policy reforms initiated in 2015 have stimulated a shift from generic to innovative drug development in China, with significant increases in R&D investment since 2018 [19][21]. - The number of First-in-Class (FIC) drugs developed in China has risen from 9 in 2015 to 120 in 2024, indicating a substantial increase in innovation [25][26]. Section 2: Continued BD Opportunities - PD-(L)1 plus is identified as a cornerstone for next-generation cancer treatments, with significant demand and potential for new products [51]. - The report notes that ADCs are transitioning towards more differentiated targets, focusing on unmet clinical needs, with promising candidates like PD-L1, DLL3, and EGFR [51]. - The GLP-1 market is experiencing rapid growth, with a focus on multi-target, oral, combination, and long-acting formulations [51]. Section 3: Investment Recommendations - For PD-(L)1 plus, companies such as Kangfang Biotech, Shansheng Pharmaceutical, and Junshi Biosciences are recommended for investment due to their strong pipelines [5]. - In the ADC space, companies like Fuhong Hanlin and Zai Lab are highlighted for their potential in addressing unmet clinical needs [5]. - In the GLP-1 sector, firms such as Borui Pharmaceutical and Zai Lab are noted for their promising developments [5].

金十图示：2025年08月01日（周五）富时中国A50指数成分股今日收盘行情一览：银行股走势分化，石油、证券、医药股走软 富时中国A50指数连续 光大银行 2392.96亿市值 6.38亿成交额 4.05 0.00(0.00%) 保险 中国太保 中国平安 中国人保 机械 3608.68亿市值 3569.15亿市值 10598.36亿市值 9.02亿成交额 28.60亿成交额 6.15亿成交额 58.20 37.10 8.16 -0.36(-0.96%) -0.49(-0.83%) -0.02(-0.24%) 酿酒行业 贵州茅台 山西汾酒 五粮液 17800.32亿市值 2182.64亿市值 4696.75亿市值 42.01亿成交额 9.39亿成交额 14.91亿成交额 1417.00 178.91 121.00 -4.67(-0.33%) -0.09(-0.05%) -0.15(-0.12%) 半导体 海光信息 北方华创 寒武纪-U HYGON 2379.85亿市值 2882.85亿市值 3201.78亿市值 49.98亿成交额 18.35亿成交额 31.52亿成交额 329.80 689.10 137.75 ...

Core Insights - The State Council held a meeting on July 31, 2025, to implement personal consumption loan interest subsidy policies and service industry loan interest subsidy policies, aimed at reducing credit costs for residents and financing costs for service industry entities, thereby stimulating consumption potential and enhancing market vitality [1] Group 1: Beneficiary Analysis - The "policy intensity - industry elasticity - valuation safety margin" three-dimensional model was constructed to identify beneficiaries, leading to three main beneficiary lines [2] - Key beneficiaries in the consumer finance infrastructure layer include: - China Merchants Bank (招商银行) with over 20% market share in consumer loans, expected to see growth in its consumer loan business due to the subsidy policy [2] - BYD (比亚迪) benefiting from reduced car purchase costs through auto loan subsidies, likely to boost sales in the electric vehicle sector [2] - Hengsheng Electronics (恒生电子) anticipated to receive numerous orders for bank subsidy system upgrades due to increased demand [2] - Tongqinglou (同庆楼), a regional restaurant leader, expected to expand operations and improve service quality due to reduced financing costs [2] - Ningbo Bank (宁波银行), which has the highest proportion of small and micro loans in the industry, will see new growth opportunities from the subsidy policy [2] Group 2: Consumption Recovery and Upgrade - Beneficiaries in the consumption recovery layer include: - Wuliangye (五粮液), a high-end liquor brand, expected to benefit from the recovery of high-end consumption in banquet scenarios [3] - Songcheng Performance (宋城演艺), a leader in the cultural tourism sector, likely to attract more visitors and enhance performance due to tourism subsidies [3] - Yili (伊利股份), a dairy industry leader, expected to benefit from the upgrade in dairy consumption and cost reductions [3] - Midea Group (美的集团), anticipated to see increased demand for home appliances due to the combination of old-for-new policies and interest subsidies [3] - Haitian Flavoring (海天味业), expected to experience growth in demand for condiments as the restaurant industry recovers [3] - Yanghe (洋河股份), benefiting from the recovery of banquet consumption in the mid-range liquor segment [3] Group 3: Long-term Value and Innovation - Beneficiaries in the consumption upgrade empowerment layer include: - Heng Rui Medicine (恒瑞医药), expected to see growth in innovative drugs and medical consumption due to increased resident spending [5] - Aier Eye Hospital (爱尔眼科), benefiting from rising demand for refractive surgery as consumer spending on eye health increases [5] - Haier Smart Home (海尔智家), anticipated to see growth in high-end smart home product sales due to interest subsidies [5] - China Duty Free Group (中国中免), expected to benefit from the recovery of inbound tourism and support for duty-free consumption [5] - Gree Electric (格力电器), likely to see increased demand for home appliances due to favorable policies and channel reforms [5] Group 4: Economic Impact - The "double interest subsidy" policy is distinct from traditional infrastructure stimulus, as it aims to precisely activate consumer demand to drive economic circulation, demonstrating stronger targeting and effectiveness [7]

-0.02(-0.35%) +0.09(+0.80%) +0.03(+0.37%) 光大银行 2392.96亿市值 3.88亿成交额 4.05 0.00(0.00%) 得經 中国太保 中国平安 中国人保 0 3626.37亿市值 10660.27亿市值 3615.32亿市值 4.24亿成交额 13.91亿成交额 3.56亿成交额 58.54 37.58 8.20 +0.12(+0.32%) -0.15(-0.26%) +0.02(+0.24%) 酿酒行业 贵州茅台 山西汾酒 五粮液 17807.86亿市值 2176.17亿市值 4692.86亿市值 25.26亿成交额 8.45亿成交额 5.58亿成交额 1417.60 178.38 120.90 -0.62(-0.35%) -4.07(-0.29%) -0.25(-0.21%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2381.29亿市值 2907.41亿市值 3220.14亿市值 12.26亿成交额 30.95亿成交额 21.51亿成交额 138.54 330.00 694.97 -5.20(-1.55%) -14.53(-2.05%) -0. ...

Group 1 - The report indicates that the "bull market atmosphere" is continuously strengthening, with the main logic of "anti-involution" significantly improving the supply-demand structure for midstream manufacturing in 2026 [6][14] - The report suggests that the conditions for residents to fully allocate equity are still lacking, but the profit effect is accelerating, potentially leading to an earlier time for comprehensive incremental speculation in A-shares [6][14] - The report recommends actively seeking new structural opportunities in the current market phase, which is seen as a transitional stage for the market to find the main structure of the bull market [6][14] Group 2 - The report highlights the "iron triangle" stocks: Ruike Laser, Giant Network, and Heng Rui Medicine, which are expected to perform well due to their strong market positions and growth potential [6][17] - Other recommended stocks include: Pengding Holdings, Yangnong Chemical, Sun Paper, Zhongmin Resources, China Shipbuilding, Maifusi (Hong Kong), and Jianfa International Group (Hong Kong) [6][17] - The report emphasizes the importance of technology with industrial trend catalysts and midstream manufacturing with improved supply-demand dynamics as key investment themes [6][14] Group 3 - The previous stock combination from July 1 to July 31, 2025, achieved a return of 5.11%, with A-shares averaging a 3.53% increase, while the Hang Seng Index saw an increase of 2.91% [6][2] - Since the first release of the stock combination on March 28, 2017, the cumulative increase has reached 322.85%, with A-shares up 251.34% and Hong Kong stocks up 809.47% [6][2] - The report provides detailed performance metrics for the recommended stocks, including market capitalization and price changes, indicating a strong performance relative to benchmarks [6][15]

值得关注的是，临近收盘时，创新医疗、爱朋医疗、三博脑科等多只脑机接口概念股直线拉升，创新医疗一度逼近涨停。从消息 面来看，当天下午，脑机接口板块迎来一则利好消息。据报道，国家医保局支持脑机接口等新技术进入临床并收费。 脑机接口概念股尾盘拉升 7月31日，临近A股尾盘时分，多只脑机接口概念股突然直线拉升，创新医疗涨幅一度达到9.62%，爱朋医疗一度涨超9%，三博 脑科、倍益康、熵基科技、南京熊猫等相关概念股均有拉升动作。 尾盘，再现异动！ 7月31日，A股三大指数集体调整，截至今日收盘，沪指下跌1.18%，深证成指跌1.73%，创业板指跌1.66%。从盘面上看，钢铁、 煤炭、有色等前期过热的板块集体大跌，AI、创新药概念股则逆市上涨。 耳鼻喉类立项指南统一设立"人工耳蜗植入费""发音装置安装费"等价格项目，鼓励医疗机构帮助更多患者"听得见、说得出"。 放射治疗类立项指南统一设立"质子放疗""重离子放疗"等价格项目，促进高端医疗设备的临床转化应用。 与此同时，为鼓励药品研发创新，国家医保局还制定了新上市药品首发价格机制。 国家医保局医药价格和招标采购司司长王 小宁表示，"我们支持高水平的创新药，在上市初期取得和高 ...